The future focus of myBioma after the follow-up investment will be on closer cooperation with already established laboratories and hospitals, whereby the software for sound microbiome analysis will be further developed and optimised for various medical indications, for example through current studies. The myBioma analysis is already successfully in use throughout Europe. During the Coronavirus pandemic in particular, many people realised that the immune system is located in the intestine and started to act independently or in combination with their doctor.
“Both the product and the team have great potential and I am confident that myBioma can help to facilitate medical treatments with its technology and accelerate recovery,” Wilckens continued.
The company is already involved with its product in clinical trials to evaluate the relevance and usefulness of the intestinal microbiome in various medical fields. In future, diagnoses or specific therapy plans will be based on the individual intestinal microbiome of patients.
“One of our short-term goals is to offer interested laboratories and hospitals a simple and cost-effective way to integrate the analysis platform developed by myBioma into their own applications using a standardised interface,” concludes Barbara Sladek, PhD (Oxford) MBA, founder and managing director of myBioma.